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patients.
We collected endoscopic GI tract biopsy samples and
matched blood for fourteen patients undergoing myelo-
blative HCT with suspected GI GVHD within one day of
corticosteroid therapy. We also collected peripheral blood
approximately thirty days after biopsy. Seven of these
patients were negative for GVHD or had mild steroid
responsive GI GVHD and seven had severe steroid refractory
GI GVHD. We extracted genomic DNA and performed TCR
beta CDR3 repertoire sequencing at Stanford and with
Gigagen GigaMune Rep-Seq, using the Illumina next gener-
ation sequencing MiSeq and HiSeq platforms.
For each patient, between 1,000-5,000 unique T cell
sequences were identiﬁed in the endoscopic tissue. We
bracketed the most frequent clones in the GI tissue samples
by rank order cut-offs and a ﬂoating measure of skewness
and followed these clones in the blood. Both methods
showed that, on average, the GI identiﬁed clones increased in
frequency more in severe patients (51.2 +/- 39.2) when
compared to mild or negative patients (3.08 +/- 2.8; see
Figure 1). Additionally, patients in both groups who received
more steroids (mg/kg/day) showed a correlated reduction in
GI identiﬁed T cell expansion in the blood over time. These
results support the use of T cell repertoire sequencing and
associated approaches in human patients to both clarify the
pathophysiology of GVHD and may provide an independent
immune biomarker that could guide GVHD therapy.
Figure 1. GI identiﬁed TCR sequences become much more frequent in the
blood in an analysis of patients with severe steroid refractory GI GVHD as
compared to a patients with steroid responsive GVHD or without GVHD. (a)
Graphical depiction of the most frequent TCR sequence identiﬁed in the colon
and blood. Top panel shows the increasing frequency of the topped rank clone
(red), in contrast to the lower panel which shows the decreasing frequency of
the top ranked clone (green). (b) The mean fold change of TCR sequences
identiﬁed in the GI tract of patients tracked in the blood at day 30 to day of
diagnosis of 7 patients with severe GVHD and 7 patients with mild or no GVHD
(Wilcoxin Test, P < .002). GI sequences were identiﬁed as the top 100 by rank
order.453
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Introduction: In allogeneic hematopoietic cell trans-
plantation (HCT), minor histocompatibility antigens (mHags)
are known to play an important role in generating immune
responses leading to graft-versus-leukaemia (GVL) effectsand graft-versus-host-disease (GVHD). mHags are results of
polymorphisms in the recipients genome, which cause
expression of peptides that can be recognised by donor T-
cells. Y-chromosomally encoded proteins constitute
a constant source of mHags relevant in allogeneic HCTs with
female donor and male recipient due to the disparities
between these and their homologue X-chromosomally
encoded counterparts.
Methods: A panel containing 8-11 mer peptides encom-
passing multiple putative and knownmHags encoded by the
Y-chromosome was designed using a bioinformatics
predictor of peptide-HLA binding, NetMHCpan. These
peptides were synthesized and used to screen for peptide-
speciﬁc T-cell responses in peripheral blood mononuclear
cells (PBMCs) obtained post-HCT from male recipients of
female donor grafts. Following in vitro stimulation, PBMCs
were analysed with an inteferon-g ELISpot assay. When
a response was found, the T-cells were further analyzed with
intracellular cytokine staining (ICS) and ﬂow cytometry to
determine whether it was a CD4- or a CD8-response. The
optimal epitope and the HLA-restriction was determined by
tetramer staining.
Results: In one male recipient of a female donor graft a T-cell
response was observed with ELISpot against the peptides
YFYYNAFHWAI and RESEEESVSL. ICS and ﬂow cytometry
revealed that both were CD8 responses. Both peptides were
earlier described mHags restricted by HLA-A*24:02 and HLA-
B60, respectively. Tetramer staining conﬁrmed that the
optimal epitopes were YYNAFHWAI and RESEEESVSL pre-
sented on HLA-A*24:02 and HLA-B*40:01 (a member of the
previously designated HLA-B60 speciﬁcity), respectively.
PBMCs obtained post HCT from ﬁve other male recipients of
female donor grafts have been analysed for T-cell responses
with ELISpot. Responses have been observed and further
analysis is ongoing.
Conclusion: Using a HLA-tetramer approach to identify the
optimal epitopes of two known mHags encoded by the Y-
chromosome as well as the presenting HLA restriction
elements at high resolution, we have demonstrated the
feasibility of a reverse immunology approach in mHag dis-
covery.454
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Pulmonary function post allogeneic hematopoietic stem cell
transplant (HSCT) can be impaired by previous exposure to
chemotherapy, infection, or graft versus host disease
(GVHD). In this retrospective study, we analyzed 21 patients
with hematologic malignancies who are long term trans-
plant survivors with a median follow-up of 48 months who
had received a related (60%) or unrelated (40%) HSCT
conditionedwith a busulfan-based regimen. Of 21 patients, 7
are of Caucasian and 14 non-Caucasian ethnicity. All patients
had routine pulmonary function tests (PFTs) repeated within
two years from transplant and none had underlying lung
disease. To eliminate inter-lab variability, all PFTs were
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analysis was 90%.
We initially compared single parameters of PFTs including
corrected diffusion limiting capacity of oxygen (DLCO), forced
expiratory volume in one second (FEV1), forced vital capacity
(FVC), FEV1/FVC ratio, and total lung capacity (TLC) obtained
before and after transplant. Post transplant, all PFT parame-
ters showed some degree of reduction compared to pre-
transplant values. FEV1 and FEV1/FVC were signiﬁcantly
decreased (108 vs 92, P ¼ .04 and 86 vs 80%, P ¼ .04, respec-
tively), with no difference between Caucasian and non-
Caucasians. Overall, median values of corrected DLCOand TLC
prior to and after transplant were only slightly reduced.
However, in non-Caucasian patients a signiﬁcant reduction of
DLCO was observed (93%31 vs 73%11, P ¼ .05).
We analyzed intra-patient changes in DLCO and FEV1 values
and no correlationwas found between these parameters and
the development of chronic GVHD.
This study shows an overall decrease in pulmonary function
in patients without apparent lung disease following a mye-
loablative busulfan-based HSCT. However, a higher risk of
a reduced DLCO was noted only among non-Caucasian
patients. At this time it is not known if this observation is due
to genetic, biologic or environmental causes.
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One hundred twenty-three children from 6 French centers
were evaluated retrospectively for the treatment of steroid-
refractory acute graft-versus-host disease (aGVHD) with
Inolimomab, a murine anti-IL2R.Hematopoietic stem cell transplantations (HSCT) were
performed between 1995 and 2012. Diseases were non
malignant inherited diseases (63%) and hematological
malignancies (37%). Median age was 4, 3 years. Donors were
MRD (27.5%), MUD (32%), mismatch-MUD (13%), Haplo-
identical (20.5%) and Cord Blood (CB) (7%). The graft source
was BM (80%), PBSC (12%) and CB (8%). 37% patients had
a myeloablative conditioning. The median time to aGVHD
was 13 days after HSCT. The baseline grade of aGVHDwas I in
19%, II 45.5%, III 25% and IV 10.5%. The median delay between
aGVHD and Inolimomab was 16 days. The median dose was
0.4mg/kg and the median treatment duration of 27 days.
We observe 55% complete responses and 14% partial
responses for a total response rate of 69% and with no side
effect. Among the responders, 26% relapse. Incidence of
infection during treatment was 19.5%.
A logistic model on complete response provide evidence of
the highpredictive negative effect of the baseline grade [Odds
Ratio (OR): 5.24]. No particular target organwas a signiﬁcant
predictive factor for treatment response or survival. However,
multi-organ involvement predicted worse survival with 34%,
45% and 52% of death for patients with one, two, and three or
more organs involved, respectively (P ¼ .234).
The observed overall survival probability was 59%, with
a median survival time of 463 days. The Overall unadjusted
survivalswere 87%, 77 %, and61%at day 100, 200, andoneyear.
Survival was also signiﬁcantly improved for responders
(Relative Risk: 0.413; P ¼ .002).
As shown by multivariate Cox model, the survival was
signiﬁcantly lower for patients with non malignant inherited
diseases [Hazard Ratio (HR) ¼2.88, P < .001] compared with
hematological malignancies, and female patients were
associated with higher mortality (HR¼1.72 , P¼ .049). For
both response and survival, the success rates were signiﬁ-
cantly increasing with year of transplantation, and non-
signiﬁcant differences were found among centers.
Chronic GVHD (cGVHD) occurred in 56% patients, extensive
in 42%. cGVHD incidence was 78%, 72% , 42% for Non
Responders, Partial Responders and Complete Responders
(Anova, P¼ .017, difference only signiﬁcant between
Complete Responders and the others). Patients with hema-
tological malignancies were observed with signiﬁcantly less
cGHVD (OR¼.29, P¼ .012).
Fifty-one patients died, 17(33%) before day 100 and 34(67%)
after day 100, mostly of infections (55%) and GVHD (51%).
In conclusion, Inolimomab is well tolerated and effective for
steroid-refractory aGVHD in pediatrics. Further randomized
studies are requires to deﬁne the optimum regimen.
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